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In silico analysis of regulatory networks
underlines the role of miR-10b-5p and its
target BDNF in huntington’s disease
Sören Müller
Abstract
Non-coding RNAs (ncRNAs) play various roles during central nervous system development. MicroRNAs (miRNAs) are a
class of ncRNAs that exert their function together with argonaute proteins by post-transcriptional gene silencing of
messenger RNAs (mRNAs). Several studies provide evidence for alterations in miRNA expression in patients with
neurodegenerative diseases. Among these is huntington‘s disease (HD), a dominantly inherited fatal disorder
characterized by deregulation of neuronal-specific mRNAs as well as miRNAs. Recently, next-generation sequencing
(NGS) miRNA profiles from human HD and neurologically normal control brain tissues were reported. Five consistently
upregulated miRNAs affect the expression of genes involved in neuronal differentiation, neurite outgrowth, cell death
and survival. We re-analyzed the NGS data publicly available in array express and detected nineteen additional
differentially expressed miRNAs. Subsequently, we connected these miRNAs to genes implicated in HD development
and network analysis pointed to miRNA-mediated downregulation of twenty-two genes with roles in the
pathogenesis as well as treatment of the disease. In silico prediction and reporter systems prove that levels of BDNF, a
central node in the miRNA-mRNA regulatory network, can be post-transcriptionally controlled by upregulated
miR-10b-5p and miR-30a-5p. Reduced BDNF expression is associated with neuronal dysfunction and death in HD.
Moreover, the 3’UTR of CREB1 harbors a predicted binding site for these two miRNAs. CREB1 is similarly downregulated
in HD and overexpression decreased susceptibility to 3-nitropropionic-induced toxicity in a cell model. In
contradiction to these observations, it is presumed that miR-10b-5p upregulation in HD exerts a neuroprotective role
in response to the mutation in the huntingtin gene. Therefore, the function of miR-10b-5p and especially its effect on
BDNF expression in HD requires further academic research.
Keywords: Huntington, miRNA, Sequencing, Post-transcriptional regulation
Introduction
Huntington’s disease (HD) is a fatal hereditary neurode-
generative disorder characterized by unwanted choreatic
movements, behavioral manifestations and dementia [1].
In the caucasian populationHD appears with an incidence
of one per 10,000-20,000 per year in middle age (30-50
years) [2]. The disease is caused by a genetic disorder. An
elongation of the CAG trinucleotide repeat (36 repeats or
more) is observed within the coding region of the hunt-
ingtin (HTT) gene [3]. This mutation yields a protein with
deleterious functions for brain cells and even impairs the
Correspondence: s.mueller@bio.uni-frankfurt.de
Molecular BioSciences, University of Frankfurt, Marie-Curie-Str.9, 60439
Frankfurt a.M., Germany
ability of normal HTT to exert fundamental molecular
activities in the neurons [4]. As a consequence, neu-
rons predominantly degenerate in the brains of affected
patients [4]. While the altered biological processes finally
leading to neurodegeneration remain poorly understood,
changes in messenger RNA (mRNA) expression point to
transcriptional dysregulation as a central mechanism [5].
Beside deregulation of mRNAs, also differential expres-
sion of microRNAs (miRNAs) has been linked to HD [6].
MiRNAs are a class of small non-coding RNAs (sncR-
NAs) that can repress gene expression through transla-
tional repression or mRNA deadenylation and decay by
base pairing to partially complementary sites [7]. Recent
research has examined the role of miRNAs in HD using
next generation sequencing (NGS) and identified between
© 2014 Müller; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction
in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
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five and 85 deregulated miRNAs [8,9]. Hoss and col-
leagues [9] related five upregulated miRNAs (miR-10b-5p,
miR-196a-5p, miR-196b-5p, miR-615-3p and miR-1247-
5p) located in the HOX gene cluster to HD pathogenesis.
Nevertheless, target and differential expression analysis
with strict parameters revealed only one validated, down-
regulated target gene (KRT5) of these miRNAs. Therefore,
their function inHDpathogenesismostly remains unclear.
In order to shed light on the consequences of miRNA
deregulation in HD we used omiRas [10] to re-analyze the
dataset of Hoss and co-workers consisting of small RNA-
Sequencing (sRNA-Seq) libraries derived from twelve
HD and nine unaffected control brain tissue samples in
FASTQ format. In extension to the five miRNAs identi-
fied by Hoss and colleagues we detected nineteen addi-
tional miRNAs as differentially expressed. Furthermore,
we assigned functions to differentially expressed miR-
NAs via the interaction tool of omiRas. Analysis revealed
BDNF as a validated target of two upregulated miRNAs
(miR-10b and miR-30a), CREB1 is predicted to be post-
transcriptionally controled by the same two miRNAs.
The potential miRNA-mediated downregulation of sev-
eral major player genes in HD pathogenesis underlines the
feasibility of miRNAs as therapeutic targets in HD.
Materials andmethods
Dataset collection and preprocessing
A publicly available sRNA-Seq expression dataset of
twelve HD and nine control brain samples from the
prefrontal cortex was downloaded from Array Express
(E-MTAB-2206) in FASTQ format. The 3’ sequenc-
ing adapter (TCGTATGCCGTCTTCTGCTTGAAA) was
removed from the reads with cutadapt [11]. Subsequently,
low quality stretches below a SANGER quality score of
20 were additionally trimmed from each end of the reads
(-q 20). Only reads with a minimum length of fifteen
Table 1 DeregulatedmiRNAs in HD
miRNA NEV Control NEV HD foldChange FDR Other studies
miR-196a-5p 0.00 19.01 Inf 1.4E-010 [9,14]
miR-891a 48.39 101.39 2.10 0.00001 -
miR-10b-5p 1011.52 30689.38 30.34 0.00003 [9]
miR-4645-3p 3.66 9.44 2.58 0.0001 -
miR-1247-5p 135.61 309.04 2.28 0.0004 [9]
miR-10b-3p 0.00 5.28 Inf 0.0026 -
miR-363-3p 2239.63 3274.71 1.46 0.0033 [8]
miR-30a-3p 5223.90 6943.31 1.33 0.0048 [8]
miR-125b-2-3p 17177.77 20740.93 1.21 0.0052 -
miR-615-3p 0.00 5.45 Inf 0.0065 [9]
miR-196b-5p 1.09 10.17 9.33 0.0134 [9]
miR-127-3p 175251.70 224611.39 1.28 0.0194 -
miR-208b 75.76 112.90 1.49 0.0217 -
miR-302a-5p 2.67 6.93 2.60 0.0451 -
miR-2682-5p 212.76 299.86 1.41 0.0451 -
miR-30a-5p 171969.53 228298.92 1.33 0.0451 [8]
miR-770-5p 333.36 445.55 1.34 0.0451 -
miR-130a-3p 4740.57 6385.28 1.35 0.0451 -
miR-92b-5p 40.62 57.17 1.41 0.0451 -
miR-449a 20.31 32.65 1.61 0.0451 -
miR-3139 8.59 2.27 0.26 0.0031 -
miR-4449 10.95 2.75 0.25 0.0163 -
miR-4521 335.51 168.04 0.50 0.0194 -
miR-138-2-3p 94.11 74.60 0.79 0.0194 -
MiRNAs upregulated in HD brains are indicated by a fold-change>1, downregulated miRNAs by a fold-change<1. NEV corresponds to the normalized expression
value and FDR is the corrected p-value. Other studies indicates if any study different from this has likewise reported the miRNA deregulation in HD.
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base pairs after clipping were used for further analysis
(-m 15). A list of differentially regulated genes identified in
Microarray data of sixteen HD patients’ prefrontal cortex
and fifteen controls cases published by Hodges and co-
workers [5] was retrieved in XLS format and intersected
with a list of genes with implication in HD, as defined by
the HD crossroads database [12].
MiRNA quantification, differential expression and target
analysis
Samples were uploaded to omiRas and analyzed as
described previously [10]. In contrast to Hoss and col-
leagues we tested for differential expression in “gene-
est-only” mode of DESeq [13], which is recommended
if more than seven replicates per condition are avail-
able. MRNA targets with involvement in HD pathogenesis
(see dataset collection) of differentially expressedmiRNAs
were identified with the “interactive network tool” of omi-
Ras. An interaction between a miRNA and a coding-gene
is assumed to be valid if the following two criteria apply:
(a) Three or more of seven miRNA-mRNA interaction
databases support the interaction. (b) The expression of
the miRNA/mRNA pair is inverse. The miRNA is signif-
icantly downregulated and the mRNA is upregulated or
vice versa. Interactions between gene products of deregu-
lated genes were detected via STRING database.
Results
The results for the comparison of twelve HD and nine
control brain samples is available from omiRas (http://
tools.genxpro.net/omiras/10eea4eb58d1/results/). Our
analysis confirms the upregulation of miR-10b-5p, miR-
196a-5p, miR-196b-5p, miR-615-3p and miR-1247-5p in
HD. In addition, we detect nineteen other differentially
expressed miRNAs, of which four are down- and fifteen
upregulated. The expression values in both conditions as
well as the corrected p-value for each miRNA are given
in Table 1. The lower number of differentially expressed
miRNAs in comparison to previous studies [8,14] can be
explained by the elimination of false positive candidates
due to a reliable estimation of biological variance. The































































Figure 1MiRNA-mRNA interaction network in HD. Downregulated genes/gene products with implication in HD pathogenesis are represented
by red circles. Interactions between proteins are visualized with blue lines, predicted post-transcriptional regulation of mRNAs by miRNAs is
indicated by a dotted grey line.
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products of downregulated genes with 121 protein-
protein interactions. Hubs in the network represented
by nodes with the most protein-protein interactions are
Calmodulin 1 (CALM1) with twelve interactions and
brain-derived neurotrophic factor (BDNF) with nine
interactions. The downregulation of mRNAs coding
for the proteins in the network is potentially caused
by eight miRNAs with predicted binding sites in their
3’UTR. Approximately one third (22) of all mRNAs are
predicted targets of miRNAs, four genes can be post-
transcriptionally controlled by more than one miRNA
(BDNF, CALM1, CNR1, CREB1). The hub genes BDNF
and CALM1 harbor a binding site for miR-10b-5p, 196a-
5p, 196b-5p and 30a-5p in their 3’UTR. CREB1 and BDNF
are predicted targets of miR-10b and miR-30a, whereas
the regulation of BDNF has recently been experimentally
verified in the prefrontal cortex [15,16].
Discussion
We extend the report of Hoss and co-workers based on
NGS miRNA expression profiles of twelve HD and nine
healthy control brain samples. Re-analysis of the dataset
reveals 24 differentially expressed miRNAs in HD, 20 of
these up- and four downregulated. Regulatory network
analysis comprising genes involved in HD pathogene-
sis with decreased expression underlines the role of the
most significantly upregulated miRNA, miR-10b-5p, that
targets BDNF and CREB1.
BDNF is a secreted neurotrophic factor, which repre-
sent a class of molecules that contribute essentially to
the survival of the peripheral and central nervous sys-
tem, and reduced level of BDNF mRNA as well as protein
have been found in HD cerebral cortex and striatum
[17]. BDNF is required in striatal neurons for survival
and activity. The largest proportion of striatal BDNF
is initially produced in the frontal cortex and subse-
quently transported to the striatum [18]. YAC 128 mice
that were transplanted with BDNF overexpressing MSCs
in the striatum show a significantly reduced amount of
neuronal loss [19]. Downregulation of BDNF has been
directly associated with the mutation of wild-type HTT
[17]. Our analysis extends the regulatory mechanism lead-
ing to BDNF downregulation in HD to miR-10b-5p and
30a-5p which are significantly upregulated in HD and
have been shown to target the 3’UTR of the BDNF
transcript [15,16]. Upregulation of BDNF levels in the
striatum/cortex are a potential therapeutic strategy in
HD treatment [18] and our analysis points to an inhi-
bition of miRNAs by antagomiRs to achieve this goal.
Mir-10b antagomirs have inter alias been used for ther-
apeutic silencing of miR-10b to inhibit metastasis in a
mouse mammary tumor model [20]. In contradiction to
these observations, miR-10b-5p expression enhanced the
survival of PC12 Q73 cells and its upregulation in HDmay
be a neuroprotective response to the HTT mutation [9].
Therefore, the role of miR-10b-5p and especially its effect
on BDNF expression in HD requires further academic
research.
CREB1 encodes a transcription factor that is a mem-
ber of the leucine zipper family of DNA binding proteins.
CREB1 induces transcription of genes in response to hor-
monal stimulation of the cAMP pathway. Members of the
CREB family are essential for the maintenance of cell via-
bility in various tissues and stages of development [21].
Reduced CREB1 expression has been reported in HD
and mutant Htt represses CREB1 expression by a direct
interaction with the CREB-binding protein [22]. Lack of
CREB1 expression during development of the central ner-
vous system leads to substantial apoptosis of postmitotic
neurons [21]. The CREB signaling pathway has been sug-
gested for pharmacological intervention in neurodegener-
ative disorders like HD [21]. The 3’UTR ofCREB1 harbors
predicted binding sites of miR-10b-5p, 30a-5p and 196a-
5p, which makes antagomiRs a potential approach for
intervention in CREB signalling. Nevertheless, these inter-
actions lack experimental validation and form a basis for
further research.
Taken together our analysis underlines the role of
miRNAs in HD pathogenesis. The regulatory network
of deregulated genes and miRNAs may now spur fur-
ther research in the field of HD. We provide a set of
miRNA-mRNA interactions that currently lack experi-
mental validation and point to miRNAs that are potential
targets for treatment with antagomiRs. The validity of
the predicted interactions between downregulated genes
and upregulated miRNAs is underlined by the recent
validation of four interactions in the network (miR-10b-
5p-BDNF, miR-30a-5p-BDNF, miR-30a-5p-AP2A1, miR-
30a-5p-PPP3CA [23]).
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